Mapping the Pathways of Resistance to Targeted Therapies
Author:
- 14 October 2015
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (20) , 4247-4251
Abstract
Resistance substantially limits the depth and duration of clinical responses to targeted anticancer therapies. Through the use of complementary experimental approaches, investigators have revealed that cancer cells can achieve resistance through adaptation or selection driven by specific genetic, epigenetic, or microenvironmental alterations. Ultimately, these diverse alterations often lead to the activation of signaling pathways that, when co-opted, enable cancer cells to survive drug treatments. Recently developed methods enable the direct and scalable identification of the signaling pathways capable of driving resistance in specific contexts. Using these methods, novel pathways of resistance to clinically approved drugs have been identified and validated. By combining systematic resistance pathway mapping methods with studies revealing biomarkers of specific resistance pathways and pharmacologic approaches to block these pathways, it may be possible to rationally construct drug combinations that yield more penetrant and lasting responses in patients. Cancer Res; 75(20); 4247–51. ©2015 AACR.Keywords
This publication has 30 references indexed in Scilit:
- Rociletinib in EGFR-Mutated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Converting Cancer Therapies into Cures: Lessons from Infectious DiseasesCell, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial CellsThe American Journal of Pathology, 2012
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancerNature Chemical Biology, 2011
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007